SWK Holdings

What SWK Holdings does

SWK Holdings Corporation is a specialty finance and asset management company headquartered in Dallas, Texas, that provides bespoke capital solutions to commercial-stage healthcare and life science companies and to owners of intellectual property and royalty streams. Founded in 2012 and listed on Nasdaq under ticker SWKH until April 2026, SWK specialized in sub-$50 million structured debt, venture debt, synthetic royalties, traditional royalty monetization, and selective asset purchases, deploying approximately $780 million of capital across more than 55 parties since inception. The company also operated MOD3 Pharma (formerly Enteris BioPharma), a wholly-owned CDMO subsidiary focused on orally inhaled and nasal drug product (OINDP) formulation and manufacturing using the proprietary Peptelligence drug delivery technology, representing a vertical-integration move into operating life sciences services. The firm's revenue model is anchored in interest income from structured debt financings (typically 4-6 year terms, with warrant coverage for equity upside), royalty and synthetic royalty income, and coupon payments from its public 9.00% senior notes due 2027. SWK employs a direct enterprise field sales motion with senior investment professionals originating deals through industry referrals and life sciences networks, with typical transaction sizes of $5-20M and a roughly four-week timeline from term sheet to close. Following its April 2026 acquisition by Runway Growth Finance Corp. for $249 million, SWK Holdings ceased independent operations and became a wholly-owned subsidiary of Runway Growth Finance.

Name

SWK Holdings

Legal name

SWK Holdings Corporation

Website

https://swkhold.com

Company type

Public

Founded year

2012

Operating status

Acquired

Headcount range

1–10 employees

Short description

SWK Holdings is a Dallas-based specialty finance company providing bespoke structured debt, venture debt, and royalty financing to commercial-stage healthcare and life science companies, specializing in sub-$50 million opportunities; it was acquired by Runway Growth Finance in April 2026.

Ownership category

akta.pro rank

Product category

Healthcare Specialty Finance

NAICS

All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (523940), Management of Companies and Enterprises (55111)

SIC

Short-Term Business Credit Institutions (6153), Patent Owners & Lessors (6794)

akta.pro primary industry

Direct Lending — Asset-Based Lending (ABL) (FSAHAJAE)

akta.pro secondary industries

Business Services (B2B) Growth Equity (FSANACAD), Buy-Side Search & Acquisition Advisory (FSAEAIAD)

Keywords

• Specialty finance
• Healthcare lending
• Venture debt
• Royalty financing
• Life science capital

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Interest Income from Structured Debt Financings: SWK provides structured debt financings (venture debt, enterprise value loans) to growth-stage healthcare and life science companies. Revenue is generated through interest payments on loans, typically with variable rates and terms ranging from 4-6 years. The company also includes warrant coverage with many loans to participate in equity upside.
2. Royalty and Synthetic Royalty Income: SWK acquires existing royalty streams or structures synthetic royalties with healthcare companies. Revenue is earned as a percentage of future product sales, with caps and milestone-based structures that allow for residual royalty participation after initial returns are achieved.
3. Senior Notes Interest: SWK issued senior unsecured notes due 2027 bearing 9.00% interest rate, listed on Nasdaq under symbol SWKHL. This represents a public debt instrument generating fixed coupon payments.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SWK Holdings provides bespoke, non-dilutive capital solutions to commercial-stage healthcare and life science companies and to royalty owners. Its core offerings include structured debt financings and venture debt (including enterprise value loans) for growth-stage companies, synthetic royalties / revenue interests, traditional royalty monetization, and selective asset purchases. The company specializes in sub-$50 million opportunities, structuring deals through direct origination with senior investment professionals.

Product overview

SWK Holdings is a specialty finance and asset management company providing bespoke capital solutions for commercial-stage healthcare and life science companies and royalty owners. The company operates primarily through six interconnected financing products: Structured Debt Financings and Venture Debt for growth-stage companies lacking traditional collateral; Synthetic Royalties and Traditional Royalty Monetization for IP owners seeking liquidity; and Asset Purchase for select product acquisitions. Additionally, MOD3 Pharma operates as a wholly-owned subsidiary CDMO providing OINDP drug delivery solutions, demonstrating the company's operational involvement in the life sciences sector. The company specializes in sub-$50 million opportunities across biopharma, medical devices, diagnostics, and life science tools sectors.

Differentiator

Problem solved

Functional benefit

Brands

• MOD3 Pharma: A wholly-owned CDMO subsidiary specializing in innovative OINDP (Orally Inhaled and Nasal Drug Product) drug delivery solutions. Formerly known as Enteris BioPharma, rebranded in 2025. Operates Peptelligence drug delivery technology for oral delivery of peptides and BCS class II, III, and IV small molecules.
• Peptelligence

Products and services

• Venture Debt Non-dilutive loan financing product for earlier-stage innovative healthcare and life science companies backed by institutional equity investors; includes enterprise value loans for companies that lack hard assets or positive cash flows but have substantial enterprise values capable of supporting debt financing.
• Structured Debt Financings Recourse debt obligations for growth-stage healthcare and life science companies with commercialized products, providing more flexible credit capital than traditional lending institutions with customized terms based on each partner's specific needs.
• Synthetic Royalties / Revenue Interests Transaction structure in which SWK purchases a new royalty interest in an existing revenue stream from the marketer, allowing healthcare companies to receive up-front capital in exchange for expected future royalty payments without diluting equity.
• Traditional Royalty Monetization Allows royalty owners (institutions, inventors, or companies) to receive upfront capital in exchange for expected future royalty payments; can entail sale of all or a portion of a royalty stream, or a non-recourse loan if the owner wants to maintain future cash flows after loan repayment.
• Asset Purchase In select situations, SWK partners with an experienced operator to purchase and market an existing healthcare or life science product, enabling product acquisition and commercialization for the operating partner.
• MOD3 Pharma CDMO Services Wholly-owned SWK Holdings subsidiary operating as a fully integrated Contract Development & Manufacturing Organization (CDMO) specializing in innovative Orally Inhaled and Nasal Drug Product (OINDP) drug delivery solutions. Provides CMC expertise, drug formulation, process development, and scalable manufacturing for Phase 1 & 2 clinical trials, using the proprietary Peptelligence technology for oral delivery of peptides and BCS class II, III, and IV small molecules.
• Senior Unsecured Notes due 2027 (SWKHL) Public debt instrument issued by SWK Holdings listed on Nasdaq under ticker SWKHL, bearing a 9.00% interest rate, with net proceeds of approximately $29.1 million after underwriting discounts.

Quantifiable outcome

• Since inception, SWK and partners have completed financings with over 55 parties deploying approximately $780 million of capital.
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MOD3 Pharma (formerly Enteris BioPharma)coreStrategic or Co-development PartnerMOD3 Pharma is a wholly-owned subsidiary of SWK Holdings, rebranded in 2025 from Enteris BioPharma. It operates as a fully integrated CDMO specializing in innovative OINDP drug delivery solutions using proprietary Peptelligence technology. Enables SWK to become more operationally oriented with wholly-owned portfolio of milestones and royalties.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• SLR Investment Corp: Larger externally managed BDC providing senior secured loans to middle-market private U.S. companies. Comparable in capital structure and direct-lending focus but broader sector exposure and larger typical deal sizes than SWK.

Direct peers

• Trinity Capital: Public specialty finance company providing venture debt and equipment financing to growth-stage companies including life sciences. Overlapping sweet spot in healthcare and growth-equity-backed borrowers.
• WhiteHorse Finance: Externally managed BDC originating and underwriting loans to lower middle-market borrowers. Comparable to SWK in deal-size band and structured/sponsor-backed lending approach.
• Portman Ridge Finance: Public specialty finance (BDC) firm with comparable permanent-capital structure and focus on lower middle-market and sponsored transactions overlapping with SWK's investment profile.
• Oxford Square Capital Corp: Public BDC focused on lower middle-market companies with similar transaction-size profile to SWK's sub-$50M sweet spot; comparable in permanent-capital structure and structured debt orientation.
• Hercules Capital: The largest publicly traded specialty finance company focused on venture debt to life sciences and technology companies. Closest direct peer to SWK in deal type (structured debt, growth-stage venture loans), sector (biopharma, medtech), and use of warrants/equity participation.
• Capitala Finance: Specialty finance provider to lower middle-market companies with comparable check sizes and a structured debt orientation similar to SWK's capital solutions.
• Horizon Technology Finance: Public BDC providing venture debt to life sciences and technology companies. Directly comparable to SWK in sub-$50M check size, healthcare sector focus, and structured financing approach.
• Runway Growth Finance Corp: Direct acquirer of SWK Holdings and the most structurally comparable peer — a publicly traded specialty finance company extending loans to growth-stage companies with similar enterprise-value-backed structures and warrant economics.
• PhenixFIN Corporation: Public specialty finance company focused on senior secured loans to middle-market borrowers; comparable capital structure (permanent capital / BDC) and tailored deal origination approach.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/1049853

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SWK Holdings